Navigation Links
Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company
Date:8/17/2011

There is currently no effective FDA-approved treatment for GVHD.

Since this is a life-threatening condition, and assuming the safety and efficacy will be robust, the Company intends to apply to the FDA for approval of an advanced clinical trial that would be regarded as a pivotal trial equivalent to a Phase II/III. In addition, the Company expects to receive approval for an Orphan Drug status and Fast Track designation, which will significantly reduce the costs and shorten the development timeline towards commercialization of the product while providing additional protection from competition.

Ophir Shahaf, CEO of Hadasit Bio Holdings, said, "We are excited about the progress in Enlivex, which is one of Hadasit Bio-Holdings' most advanced portfolio companies. In addition to Enlivex's progress, we have also noticed a general trend in favor of cell therapy technologies and stem cell therapy. This area was an unfulfilled promise up until a few years ago, but has recently received recognition by major players in the field – pharmaceutical companies, regulators and investors – as a breakthrough technology with the potential to bring about real change in pharmaceutical innovation, where there has been a significant decrease in quantity and quality of effective treatments in recent years."

Alon Moran, CEO of Enlivex, added, "We are encouraged by the results observed to date, both in terms of safety and efficacy. Although the results are partial and not yet final, we will have a significant asset if the remaining results are consistent with what we have seen so far. We expect to complete the trial in the near future and are preparing for the next, larger, multi-national study. In a year's time, we may be in the midst of an advanced, substantial trial and close to agreements with strategic partners."

About Enlivex Therapeutics:

The company's first product is designed to treat Graft versus Host Disease (GVHD), which is a
'/>"/>

SOURCE Hadasit Bio-Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  Cannabis Science, Inc. (OTC: CBIS), ... development and related consulting, applauds the Editorial Board ... strong position in opposition to current federal law ... publication.  The New York Times also announces a ... exploring the issue called "High Time:  An Editorial ...
(Date:7/29/2014)... Philadelphia, PA (PRWEB) July 29, 2014 Philadelphia’s ... to help businesses get their start. The Innovation Center ... and the University City Science Center to help ... its doors on Monday, July 28. , ... corner of 34th and Market Streets, is the new home ...
(Date:7/29/2014)... 2014 Quorum Review IRB, the ... awarded accreditation by the International Association of ... Six Sigma Deployment Program. The citation recognizes robust ... , Quorum’s Lean Six Sigma program was evaluated ... designation. The designation is a public statement of ...
(Date:7/29/2014)... San Diego, CA (PRWEB) July 29, 2014 ... added to Pipette.com’s centrifugation product selection. Eppendorf 5427 R ... reverse engineering, and DNA – it is targeted towards ... the Eppendorf Centrifuge 5427 R as it compliments their ... as their Eppendorf line of microcentrifuge tubes, PCR tubes, ...
Breaking Biology Technology:Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... Nov. 1 Elbit Medical,Imaging Ltd. (Nasdaq: EMITF ... Meeting of its shareholders held today, Thursday, November,1, 2007, ... set forth in EMI,s proxy statement dated,September 6, 2007 ... approved by the required majorities, except that the,following proposals ...
... 1 Proteon Therapeutics,( http://www.proteontherapeutics.com ), a ... to address the,medical needs of patients with ... the Annual Meeting of the American Society ... (PRT-201) Dilates Outflow,Veins in a Preclinical Model ...
... free home caregiving to disabled veterans, DENVER, ... We Care For Veterans campaign to honor the ... disabled veterans. (Logo: http://www.newscom.com/cgi-bin/prnh/20070521/LAM004ALOGO ) ... 20 hours each of free in-home care services ...
Cached Biology Technology:Elbit Medical Imaging Ltd. Announces Results of Its Annual General Meeting 2Elbit Medical Imaging Ltd. Announces Results of Its Annual General Meeting 3Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007 2Homewatch CareGivers Launches 2007 We Care For Veterans Campaign 2
(Date:7/28/2014)... approved by the U.S. Food and Drug Administration (FDA) ... certain bacterial pathogens inside human cells, including those that ... findings, published in mBio , the online open-access ... new way of identifying non-antibiotic drugs that could one ... of drugs on the list inhibit the growth of ...
(Date:7/28/2014)... a circulatory problem of the legs called peripheral vascular ... surgery in serious cases. This disease can lead to ... , At The University of Texas Health Science Center ... preventative treatment in a mouse model of the disease ... Their proof-of-concept study appears in the journal Cell ...
(Date:7/28/2014)... suggests that the effects of a commonly used anesthetic ... , The study, published in this week,s issue of ... biologists at the University of California, San Diego and ... to concerns, arising from multiple studies on humans over ... may increase their susceptibility to long-term cognitive and behavioral ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... Since Moffat and Ramsden for the first time discovered ... 1977, over the last two decades, great progress has ... Jrgensen and Mathiesen were the first authors to note ... in adult Australian parrots. Later, Roberson et al studied ...
...  DiscoveRx Corporation, through its BioSeek division, today announced ... assay platform for oncology research. Consisting of primary ... panel enables researchers to easily assess the phenotypic ... to better predict in vivo drug ...
... plants, the growth of organs such as roots, leaves ... reservoir-like compartments hold stem cells, which have the ability ... At Cold Spring Harbor Laboratory (CSHL), Professor David ... insights about how plants regulate their growth. This work ...
Cached Biology News:DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research 2DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research 3In odd-looking mutant, clues about how maize plants control stem cell number 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... ICE-family proteases/caspases initiates apoptosis in mammalian cells. ... Kit provides a simple and convenient means ... cytometry in intact cells. The assay ... residues linked to rhodamine 110 (D2R), a ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: